Alnylam Pharmace. sell Biotechhunter
Summary
This prediction ended on 24.08.20 with a price of €111.76. With a performance of -2.83%, the SELL prediction by Biotechhunter was trending in the right direction. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | -6.395% | -6.395% | 18.100% | 39.937% |
iShares Core DAX® | -3.429% | 3.133% | 15.455% | 14.827% |
iShares Nasdaq 100 | -6.121% | -1.433% | 16.794% | 27.167% |
iShares Nikkei 225® | -7.364% | 1.018% | 8.293% | -2.680% |
iShares S&P 500 | -4.366% | 0.247% | 18.541% | 32.687% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.